Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205035 · ClinicalTrials.gov registry record · Phase 2
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
A Phase 2 study of Retinal Diseases and Telangiectasis, sponsored by Eye Center of Northern Colorado, P.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01205035: Completed Phase 2 study of Retinal Diseases and Telangiectasis, sponsored by Eye Center of Northern Colorado, P.C..
NCT01205035 is a Phase 2 study of Retinal Diseases and Telangiectasis that has completed, run by Eye Center of Northern Colorado, P.C.. The registered enrollment target is 6 participants, below the 396-participant average among 8 other Retinal Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01205035, a Phase 2 study of Retinal Diseases and Telangiectasis, has completed, sponsored by Eye Center of Northern Colorado, P.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Idiopathic Parafoveal Telangiectasia (IPT) \[also known as Idiopathic Perifoveal Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia (MacTel)\] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass classification of macular telangiectasias (Reference 1,5) - a bilateral, but not always symmetric disorder. It is characterized in its early stages by dilation and loss of parafoveal capillaries accompanied by angiographic leakage, "right angle" venules, central and parafoveal intraretinal cysts.
Conditions Studied
Interventions
- DRUG ranibizumab 2.0mg
Study Locations (1)
Colorado
- Eye Center of Northern Colorado - Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01205035 record still lists
NCT01205035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 396-participant average among 8 other Retinal Diseases trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Retinal Diseases appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab 2.0mg is the first listed.
NCT01205035 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01205035 about?
NCT01205035 is a clinical study titled "High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia". Idiopathic Parafoveal Telangiectasia (IPT) \[also known as Idiopathic Perifoveal Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia (MacTel)\] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass classification of macular telangiectasi...
What is the current status of trial NCT01205035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-10. Estimated completion is 2012-10.
What conditions does trial NCT01205035 study?
This clinical trial studies the following conditions: Retinal Diseases, Telangiectasis.
What interventions are being tested in trial NCT01205035?
The interventions under investigation include: ranibizumab 2.0mg (DRUG).
Who is sponsoring clinical trial NCT01205035?
This trial is sponsored by Eye Center of Northern Colorado, P.C., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01205035 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01205035's enrollment target sits among peer trials
6 8th of 8 higher than 1 of 8 other Retinal Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinal Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
RECRUITING
-
4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800
RECRUITING · NA
-
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia